How ViiV Healthcare plans to ‘show up even better’ in the fight against HIV in Black communities
Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV ...
GlobalData on MSN2mon
ViiV Healthcare shares results from trial of Dovato and three-drug therapy for HIVUK-based pharmaceutical company ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of ...
GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge ... injected every eight weeks in a formulation that the company hopes will be more appealing than Gilead’s daily ...
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...
A patent dispute between ViiV Healthcare and Gilead Sciences ... down to lingering effects of the pandemic on healthcare consultations, but the company's cell therapy franchise – Yescarta ...
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as ...
ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...
GlobalData on MSN5d
ViiV Healthcare and J&J’s adolescent HIV-1 combo gains EC authorisationThe European Commission (EC) has authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus ...
London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback